ACELLULAR DERMAL MATRICES MARKET ANALYSIS

Market News

Global Acellular Dermal Matrices Market: Key Developments

• In April 2021, Integra LifeSciences Holdings Corporation, a global medical technology company and manufacturer of SurgiMend Collagen Matrix, issued a statement in response to the U.S. Food and Drug Administration (U.S.FDA) safety communication on the differences in the complication rates between acellular dermal matrix (ADM) products used in implant-based breast reconstruction. SurgiMend Collagen Matrix is approved by the U.S. FDA for use in specific types of operations to fortify tissue where weakness occurs such as cosmetic and reconstructive surgery and hernia repair.
• In December 2021, Aziyo Biologics, Inc., a commercial-stage regenerative medicine company, announced the completion of previously announced private investment in public equity (PIPE) funding. The PIPE financing was initiated by a fund linked with Birchview Capital, an investment management company with participation from existing investors such as funds affiliated with Deerfield Management Company, an investment firm and HighCape Capital, a growth equity fund.
• In July 2020, Organogenesis Holdings Inc., a regenerative medicine company that provides  a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, announced that the most recent advanced wound care research on its Apligraf, Affinity, Dermagraft, Nushield, and PuraPly AM product lines were showcased at the 2020 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society Virtual Experience held on July 24-26, 2020 in Florida, U.S.